Companion Animal Cancer Services
Cancer is a leading cause of death in cats and dogs. One out of four pets will develop cancer in their lifetime. Pets are increasingly receiving advance medical care like chemotherapy. Insurance is becoming more common to cover and protect against expensive veterinarian treatment. While there are many clinical trials that provide guidelines for treating cancer patients, there have been very few clinical trials involving chemotherapy in companion animals.
Pets are frequently considered valuable members of families with the expressed desire to prolong a pet’s quality of life. The type of chemotherapy selected is typically determined by examining the histology or the microscopic image of cancer tissue after it has been killed with chemical fixatives. However, this diagnostic approach poses significant limitations because it does not provide personalized, diagnostic information of which chemotherapy or combination of chemotherapy is best suited to kill a pet’s cancer. Treating cancer with ineffective chemotherapy leads to unwanted cost and adverse side effects.
CET has developed cutting-edge diagnostic cancer technologies to determine which single chemotherapy and combination of chemotherapy is the most effective in killing cancer cells. CET will develop a personalized living cancer cell line from a sample of fresh tumor provided by the veterinarian. The sample of fresh cancer tissue is shipped overnight on ice to CET’s processing facility where cancer cells are extracted and grown in petri dishes that can be subsequently tested against a battery of standard chemotherapy. CET then determines the most effective single drug; the best combination of two drugs; and the drug concentrations that effectively kill the animal’s cancer.